CD4/MHC Class II, CD8/MHC Class I). Pathogenic Steps Inhibited by Efalizumab: (a) T-cell activation by antigen in the lymph nodes, (b) T-cell binding to the endothelium with migration into the ...
At present there is no broad consensus on whether the apparent 'preoccupation' of the TCR repertoire with MHC molecules is due to the coligation of CD4 or CD8 coreceptors and the TCR by MHC ...